Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06429761 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Study acronym: STRIDE
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Study sites: 6 to 7v10 Show 1 more changeShow less
    • Study sites: 6 to 7
  2. Study sites: 4 to 6v9
  3. 4 versions Re-verified since May 29, 2025, no change to tracked fieldsv5-v8
  4. Study sites: 3 to 4v4
  5. Site details revised at 2 of 3 sites Study title shortened, about 21 wordsv3 Show 1 more changeShow less
    • Study title shortened, about 21 words

    See this version in full on ClinicalTrials.gov ↗

  6. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Apr 30, 2026 to Oct 31, 2026 · Start date changed from estimate of Sep 30, 2024 to Jan 2, 2025 · Study sites: 0 to 3v2 Show 3 more changesShow less
    • Primary and study completion dates: Apr 30, 2026 to Oct 31, 2026
    • Start date changed from estimate of Sep 30, 2024 to Jan 2, 2025
    • Study sites: 0 to 3
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN
Trial Details
NCT Number NCT06429761
Lead Sponsor AstraZeneca
Conditions BREAST CANCER
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov